Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-01
2006-08-01
Murphy, Joseph (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S297000, C514S299000, C514S648000
Reexamination Certificate
active
07084106
ABSTRACT:
The present invention provides a novel treatment for senile dementia (Alzheimer's Type), comprising administering an anti-complement protein to a patient in need of such treatment in an amount sufficient to inhibit the complement cascade and thereby inhibit the production or enlargement of amyloid plaques in the brain of the patient. The present invention further provides pharmaceutical compositions comprising anti-complement protein, or derivatives thereof, and/or pharmaceutically acceptable salts thereof in a variety of unique pharmaceutical dosage forms.
REFERENCES:
patent: 4609647 (1986-09-01), Growdon et al.
patent: 5157110 (1992-10-01), Kotwal et al.
patent: 5187268 (1993-02-01), Kotwal et al.
patent: 5807671 (1998-09-01), Soreq et al.
patent: 5855882 (1999-01-01), Li et al.
Daly J 4th, Kotwal GJ. Pro-inflammatory complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging. 1998 Nov.-Dec.;19(6):619-27.
Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav. 2001 Aug.;73(5):873-86.
Adams, “Alzheimer's Disease Research: A Game of Connect the Dots,”Gerontology, 1997, 43:8-19.
Beal et al., “Alzheimer's Disease and Other Dementias,”Harrison's Principles of Internal Medicine, 13thEdition, vol. 2, Chapter 370, pp. 2269-2275, 1998.
Beyreuther and Masters, “Serpents on the road to dementia and death,”Nature Med., 1997, 3(7):723-725.
Breitner et al., “Delayed Onset of Alzheimer's Disease With Nonsteroidal Anti-Inflammatory and Histamine H2 Blocking Drugs,”Neurobiol. Aging, 1995, 16(4):523-530.
Buxbaum and Greengard, “Regulation of APP Processing by Intra- and Intercellular Signals,”Ann. N.Y. Acad. Sci., 1996, 777:327-331.
Cheng, “A heparin-binding protein in porcine seminal plasma stimulates neurite outgrowth on neuroblastoma cells in culture,”Neurosci. Lett., 1992, 142:77-80.
Citron et al., “Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice,”Nature Med., 1997, 3(1):67-72.
Corder et al., “Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families,”Science, 1993, 261:921-923.
Cotman et al., “β-Amyloid Converts an Acute Phase Injury Response to Chronic Injury Responses,”Neurobiol. Aging, 1996, 17(5):723-731.
Cribbs et al., “Complement activation by cross-linked truncated and chimeric full-length β-amyloid,”NeuroReport, 1997, 8:3457-3462.
Dragunow and Preston, “The role of inducible transcription factors in apoptic nerve cell death,”Brain Res. Rev., 1995, 21:1-28.
Elkabes et al., “Brain Microglia/Macrophages Express Neurotrophins that Selectively Regulate Microglial Proliferation and Function,”J. Neurosci., 1996, 16:2508-2521.
Farias et al., “Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau,”Mol. Cell. Biochem., 1997, 168:59-66.
Goebel et al., “The Complete DNA Sequence of Vaccinia Virus,”Virology, 1990, 179(1):247-266.
Jiang et al., “βAmyloid Activates Complement by Binding to a Specific Region of the Collagen-Like Domain of the Clq A Chain,”J. Immunol., 1994, 152(10):5050-5059.
Kotwal and Moss, “Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins,”Nature, 1988, 335:176-178.
Kotwal et al., “The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation,”Mol. Cell. Biochem., 1998, 185:39-46.
Kotwal et al., “Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia Virus,”Science, 1990, 250:827-830.
Kotwal et al., “Intracellular Detection of the C-Terminal Tail Containing APP Polypeptides in AD Brain Tissue,”Soc. Neurosci. Abstr., 1996, 22:502, Abstract No. 204.2.
Kotwal et al., “Mapping and Insertional mutagenesis of a Vaccinia Virus Gene Encoding a 13,800-Da Secreted Protein,”Virology, 1989, 171(2):579-587.
Kotwal et al., “Vaccinia virus complement control protein is a virokine with lysozyme-like heparin-binding activity: possible implications in prolonged evasion of host immune response,”10th International Congress of Immunology, New Delhi, India, Nov. 1-6 1998, 1:315-320.
Kotwal, “The Great Escape. Immune Evasion by Pathogens,”The Immunologist, 1996, 4:157-164.
Mackenzie and Munoz, “Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging,”Neurology, 1998, 50(4):986-990.
Mahley et al., “Apolipoprotein E. Structure, Function, and Possible Roles in Alzheimer's Disease,”Ann. N. Y. Acad. Sci., 1996, 777:139-145.
Mann et al., “Microglial cells and amyloid β protein (Aβ) deposition: association with Aβ40-containing plaques,”Acta Neuropathol., 1995, 90(5):472-477.
Massung et al., “Analysis of the Complete Genome of Smallpox Variola Major Virus Strain Bangledesh-1975,”Virology, 1994, 201(2):215-240.
Massung et al., “Terminal Region Sequence Variations in Variola Virus DNA,”Virology, 1996, 221:291-300.
McGeer et al., “Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies,”Neurology, 1996, 47:425-432.
McKenzie et al., “Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein,”J. Infect. Dis., 1992, 166:1245-1250.
Messing et al., “A system for shotgun DNA sequencing,”Nucl. Acids Res., 1981, 9:309-321.
Miller et al., “Severe and Prolonged Inflammatory Response to Localized Cowpox Virus Infection in Footpads of C5-Deficient Mice: Investigation of the Role of Host Complement in Poxvirus Pathogenesis,”Cell. Immunol., 1995, 162:326-332.
Miller et al., “The Cowpox Virus-Encoded Homolog of the Vaccinia Virus Complement Control Protein Is an Inflammation Modulatory Protein,”Virology, 1997, 229(1):126-133.
Mulligan and Berg, “Expression of a Bacterial Gene in Mammalian Cells,”Science, 1980, 209:1422-1427.
Palmert et al. “Amyloid Protein Precursor Messenger RNAs: Differential Expression in Alzheimer's Disease,”Science, 1988, 241:1080-1084.
Peskind, “Neurobiology of Alzheimer's Disease,”J. Clin. Psychiatry, 1996, 57:(Suppl. 14): 5-8.
Rebeck et al., “Multiple, Diverse Senile Plaque—associated Proteins Are Ligands of an Apolipoprotein E Receptor, the α2-Macroglobulin Receptor/Low-Density-Lipoprotein Receptor-related Protein,”Ann. Neurol., 1995, 37(2):211-217.
Rohan de Silva and Patel, “Presenilins and early-onset familial Alzheimer's disease,”NeuroReport, 1997, 8(8):i-xii.
Roses, “Alzheimer's Disease: The Genetics of Risk,”Hosp. Pract., 1997, 32(7):51-69.
Shchelkunov et al., “The Genomic Sequence Analysis of the Left and Right Species-Specific Terminal Region of a Cowpox Virus Strain Reveals Unique Sequences and a Cluster of Intact ORFs for Immunomodulatory and Host Range Proteins,”Virology, 1998, 243:432-460.
Schellenberg et al., “APP717, APP693, and PRIP Gene Mutations Are Rare in Alzheimer Disease,”Am. J. Hum. Genet., 1991, 49:511-517.
Schmidt et al., “Chemical and Immunological Heterogeniety of Fibrillar Amyloid in Plaques of Alzheimer's Disease and Down's Syndrome Brains Revealed by Confocal Microscopy,”Am. J. Pathol., 1995, 147(2):503-515.
Selkoe, “The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β-Proteina,”Ann. N.Y. Acad. Sci., 1996, 777:57-64.
Selkoe, “Amyloid β-Protein and the Genetics of Alzhei
Daly, IV James
Kotwal Girish J.
Fish & Richardson P.C. P.A.
Murphy Joseph
University of Louisville Research Foundation Inc.
LandOfFree
Application of a viral complement inhibitory protein in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Application of a viral complement inhibitory protein in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Application of a viral complement inhibitory protein in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669002